Drug Profile
Namitecan
Alternative Names: ST 1968Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sigma-tau SpA
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Switzerland (IV, Infusion)
- 10 Dec 2011 Sigma tau completes a phase I trial in Solid tumours in Switzerland (NCT01748019)
- 16 Nov 2011 Pharmacodynamics data from a Preclinical trial in Paediatric sarcoma presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)